Shares of Glenmark Pharmaceuticals are likely to remain in focus on Thursday after its innovation arm, Ichnos Glenmark Innovation (IGI), announced a new development candidate, ISB 2301, aimed at treating multiple solid tumor indications.
IGI, a global clinical-stage biotechnology company focused on developing Multispecific™ antibodies in oncology, introduced ISB 2301 as a first-in-class multispecific immune cell activator designed to engage both T cells and natural killer (NK) cells to attack cancer cells.
According to the company, ISB 2301 simultaneously targets three tumor-associated antigens, a strategy aimed at overcoming the biological complexity of solid tumors that conventional immunotherapies often struggle to address.
Lida Pacaud, MD, President and Chief Executive Officer of IGI, said the therapy was engineered to deliver multi-mechanistic precision by activating both T cells and NK cells while targeting multiple antigens at the same time.
The biotechnology firm stated that ISB 2301 has demonstrated strong pharmacokinetics, tolerability, and a favorable safety profile in non-human primate studies. The therapy is also designed to induce potent antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and a sustained type 1 immune response.
The candidate has been developed using IGI’s proprietary BEAT® technology platform, which enables the manufacturing of next-generation multispecific antibodies through a standard production process.
IGI plans to file an Investigational New Drug (IND) submission for ISB 2301 by the end of 2026 and expects to begin clinical studies in 2027.